PDGFRA and neoplasm: Sunitinib (SU11248) it is an orally bioavailable inhibitor that affects the receptor tyrosine kinases involved in tumour proliferation and angiogenesis, including vegf receptors 1, 2, 3, and pdgfra and pdgfrb.